WO2013077620A1 - 수불용성 겔 조성물 및 그 제조방법 - Google Patents
수불용성 겔 조성물 및 그 제조방법 Download PDFInfo
- Publication number
- WO2013077620A1 WO2013077620A1 PCT/KR2012/009853 KR2012009853W WO2013077620A1 WO 2013077620 A1 WO2013077620 A1 WO 2013077620A1 KR 2012009853 W KR2012009853 W KR 2012009853W WO 2013077620 A1 WO2013077620 A1 WO 2013077620A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- water
- insoluble gel
- composition
- crosslinking
- weight
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Definitions
- the present invention relates to a water insoluble gel composition and a method for preparing the same, and more particularly, to a method for preparing a water insoluble gel composition by mixing a water-soluble polysaccharide, an epoxy crosslinking agent, a basic compound and a solvent and vacuum drying at low temperature.
- Polysaccharide is a natural water-soluble polymer that is a repeating unit constituting the saccharide, it is difficult to maintain a high content of the polysaccharide contained in the composition, such as lotions, ointments, creams, solutions due to the high viscosity when the aqueous solution. High viscosity makes it difficult to ensure mixing uniformity of the mixture in the composition.
- the rate of biodegradability is very important for the composition to be implanted in biological tissue. Substances implanted in living tissue should be non-toxic and require degradation and lending by in vivo metabolic activity after completing the required function.
- Hyaluronic acid a typical polysaccharide, is known to be released after metabolism at most 3 days to 4 days after insertion or transplantation in the human body, regardless of the molecular weight of hyaluronic acid and the concentration of the composition hyaluronic acid.
- the short metabolic period of hyaluronic acid is not only suitable for bioremediation materials requiring several months or more in the human body, but also as an anti-tissue adhesion agent that requires a maintenance period of about 7 to 10 days.
- the problem to be solved when making a composition containing a high concentration of polysaccharides is a high viscosity that occurs when the polysaccharide is dissolved in water.
- a method of lowering the molecular weight of the polysaccharide, a method of increasing the osmotic pressure in the aqueous solution, and a method of dispersing the polysaccharide into a fine powder state have been developed.
- Crosslinking technologies developed to convert polysaccharides, which are water-soluble polymers, to water-insoluble gels, are used to discover new crosslinking agents, control the molecular weight of polysaccharides, control the concentration of polysaccharides in crosslinking reaction solutions, control crosslink density, induce crosslink density nonuniformity, and It can be classified as a technique for controlling the type of chemical bond.
- a common method used to convert hyaluronic acid to a water insoluble gel is to mix hyaluronic acid and an epoxy-based crosslinking agent with water having a pH of 12 or higher and maintain a temperature of about 40 to 60 ° C. for several hours.
- This crosslinking process has the advantage of promoting the reaction between the epoxy-based crosslinking agent and hyaluronic acid, but the disadvantage is that the mechanical strength of the water-insoluble gel finally obtained by reducing the molecular weight of hyaluronic acid by the strong base solution and heating.
- high molecular weight hyaluronic acid of about 3 million daltons may be used instead of the 1 million daltons of hyaluronic acid, which is commonly used.
- the pH of the solution in which the hyaluronic acid is dissolved is lowered to 12 or less, or the reaction temperature is lower than 40 °C.
- the pH or the reaction temperature is lowered, the time required for the crosslinking reaction becomes too long, or the amount of the crosslinking agent increases.
- Another method for overcoming the decrease in molecular weight of polysaccharides such as hyaluronic acid, which is a disadvantage of the crosslinking reaction in the strong base solution, is to dissolve the hyaluronic acid and the epoxy-based crosslinking agent in weakly basic or distilled water or acidically controlled water having a pH of 9 or less. Techniques for drying at room temperature have also been introduced. Through this technique, even a very small amount of crosslinking agent was able to obtain a hyaluronic acid gel having a total swelling weight of 2 times or less compared to dry weight.
- the present invention is to provide a method for producing a novel water-insoluble gel composition to maximize the crosslinking density while minimizing the molecular weight decrease of the polysaccharide during the crosslinking process.
- the present invention comprises the steps of mixing a water-soluble polysaccharide, an epoxy crosslinking agent, a basic compound and a solvent;
- It provides a method for producing a water-insoluble gel composition comprising a; the step of removing the solvent by vacuum drying the mixture at 1 to 30 °C.
- the vacuum drying may be made under 1 to 30mmHg.
- the step of removing the solvent may be to concentrate the concentration of the water-soluble polysaccharide to 50 to 99% by weight.
- the water-soluble polysaccharide may have a molecular weight of 500,000 to 5 million Daltons.
- the water-soluble polysaccharide may be 1 to 100 parts by weight based on 100 parts by weight of the solvent.
- the water-soluble polysaccharide is hyaluronic acid (hyaluronic acid), hyaluronic acid salt, poly gamma glutamic acid (poly- ⁇ -glutamic acid), poly gamma glutamate, agar (agar), alginic acid (alginic acid) Alginate, carrageenan, percellaran, pectin, arabic gum, karaya gum, tragacanth gum, gati rubber (ghatti gum), guar gum, locust bean gum, psyllium seed gum, gelatin, chitin, dextran, xanthane gum, chitosan, chitosan-4-sulfate (chondroitin-4-sulfate), chondroitin-6-sulfate (chondroitin-6-sulfate) and starch (starch) may be one or more selected from the group consisting of. .
- the epoxy crosslinking agent may be from 0.01 to 60 mole parts relative to 1 mole of the hydroxyl group in the water-soluble polysaccharide.
- the epoxy crosslinking agent epichlorohydrin (epichlorohydrin), epibromohydrin (epibromohydrin), butanediol diglycidyl ether (1,4-butandiol diglycidyl ether), ethylene glycol diglyci Ethylene glycol diglycidyl ether, hexanediol diglycidyl ether, 1,6-hexanediol diglycidyl ether, propylene glycol diglycidyl ether, polyethyleneglycol diglycidyl ether diglycidyl ether, polypropylene glycol diglycidyl ether, polytetramethylene glycol diglycidyl ether, neopentyl glycol diglycidyl ether, Polyglycerol polyglycidyl ether, diglycerol polyglycidyl ether, glycerol polyglycol Glycerol polyg
- the basic compound may be a compound containing an alkali metal including sodium, potassium, calcium, lithium.
- the present invention also provides a water insoluble gel composition
- a water insoluble gel composition comprising a water soluble polysaccharide, an epoxy crosslinker, a basic compound and a solvent.
- the water-soluble polysaccharide may have a molecular weight of 500,000 to 5 million Daltons.
- the water-soluble polysaccharide may be 1 to 100 parts by weight based on 100 parts by weight of the solvent.
- the epoxy crosslinking agent may be from 0.01 to 60 mole parts based on the hydroxyl group in the water-soluble polysaccharide.
- the composition may comprise 1 to 20% by weight of the water-insoluble gel relative to the total weight of the composition.
- the composition may be transparent when the swelling degree of the water-insoluble gel is 30 to 200, translucent milky white when the swelling degree is 10 to 30 and opaque white when the swelling degree is 2 to 10.
- composition when the composition is swelled and autoclaved in a phosphate buffer of pH 6.5 to 7.5, 70 to 99% by weight relative to the weight of the composition initially added may remain as a water insoluble gel. .
- the swelling weight of the composition may be 2 to 200 times the dry weight of the water-insoluble gel remaining after autoclaving.
- the preparation method of the water-insoluble gel composition of the present invention while using a small amount of the crosslinking agent, it is possible to obtain a water-insoluble gel having excellent strength and stability by minimizing the molecular weight reduction of polysaccharides and maximizing the crosslinking density.
- the flowability of the composition can be secured. Therefore, cosmetics, health foods, pharmaceuticals, etc. can overcome the decrease in feeling due to the mixing heterogeneity during the composition manufacturing process that occurs when mixing a large amount, such as 2 to 3% by weight or more, flow loss occurs when using the composition .
- composition consisting of polysaccharides when implanted in the raw vegetables to be stably stayed for at least 10 days to several months, it can be used for tissue repair compositions, anti-adhesion agents after surgery, intraocular synovial substitutes and the like. In addition, it is stable to autoclave sterilization, which is required to be used as an in vivo implant, and also has excellent economic efficiency.
- 1 is a graph showing the volume maintenance period of the hyaluronic acid composition according to an embodiment of the present invention.
- the present invention comprises the steps of mixing a water-soluble polysaccharide, an epoxy crosslinking agent, a basic compound and a solvent; It provides a method for producing a water-insoluble gel composition comprising a; and removing the solvent by vacuum drying the mixture at 1 to 30 °C.
- a water-soluble polysaccharide, an epoxy crosslinking agent, a basic compound, and a solvent are mixed.
- the water-soluble polysaccharide is a water-soluble polymer having a saccharide as a repeating unit and having a molecular weight of 500,000 Daltons (dalton, Da) to 5 million Daltons. If the molecular weight is less than 500,000 daltons, the water-insoluble gel is not formed, or even if formed, the water-insoluble gel is extinguished during autoclaving. If the molecular weight is more than 5 million daltons, the viscosity of the solution in which the water-soluble polysaccharide is dissolved is too high to obtain mixed uniformity.
- Water-soluble polysaccharides are polymers having a property of easily decreasing molecular weight due to heat, pH and microbial contamination.
- the molecular weight that is, the final molecular weight determined after completion of the process performed for crosslinking rather than the molecular weight introduced as a raw material, that is, the crosslinking and washing, should be considered as a variable. Therefore, in the present invention it was confirmed through the viscosity measurement that the molecular weight of the water-soluble polysaccharide is changed by the crosslinking process. This can be confirmed in the experimental example to be described later.
- the water-soluble polysaccharide is not particularly limited, but hyaluronic acid (hyaluronic acid), hyaluronic acid salt, poly-gamma glutamic acid (poly- ⁇ -glutamic acid), poly gamma glutamate, agar (algar), alginic acid (alginic acid), alginate alginate, carrageenan, percellaran, pectin, arabic gum, karaya gum, tragacanth gum, gatitti gum ), Guar gum, locust bean gum, psyllium seed gum, gelatin, chitin, dextran, xanthane gum, Chitosan (chitosan), chondroitin-4-sulfate (chondroitin-4-sulfate), chondroitin-6-sulfate (chondroitin-6-sulfate) may be one or more selected from the group consisting of starch (starch). It is especially preferable that it is hyaluronic
- the water-soluble polysaccharide is preferably 1 to 100 parts by weight, more preferably 5 to 40 parts by weight based on 100 parts by weight of the solvent. If the water-soluble polysaccharide is contained in less than 1 part by weight, bumping occurs easily when dried under vacuum conditions, and industrial use is difficult. When the water-soluble polysaccharide is contained in an amount exceeding 100 parts by weight, the viscosity of the solution in which the water-soluble polysaccharide is dissolved increases the uniformity. Hard to get
- the epoxy crosslinking agent refers to a compound containing two or more epoxy functional groups.
- epoxy crosslinking agent is not particularly limited, epoxy epichlorohydrin, epibromohydrin, butanediol diglycidyl ether (1,4-butandiol diglycidyl ether), and ethylene glycol diglycidyl ether (ethylene glycol diglycidyl ether), hexanediol diglycidyl ether (1,6-hexanediol diglycidyl ether), propylene glycol diglycidyl ether, polyethyleneglycol diglycidyl ether ), Polypropylene glycol diglycidyl ether, polytetramethylene glycol diglycidyl ether, neoopentyl glycol diglycidyl ether, polyglycerol Polyglycerol polyglycidyl ether, diglycerol polyglycidyl ether, glycerol Glycerol polyglycidyl ether, trimethlypropane polyglycidyl
- the epoxy crosslinking agent may be 0.01 to 60 mole parts, preferably 0.05 to 40 mole parts, and more preferably 0.1 to 20 mole parts with respect to 1 mole of the hydroxy group in the water-soluble polysaccharide. That is, the content is determined with respect to the number of moles of crosslinkable hydroxy functional groups present in the repeating unit constituting the water-soluble polysaccharide.
- the actual reaction amount between the epoxy crosslinking agent and the polysaccharide during the crosslinking process is more important than the amount of the epoxy crosslinking agent added to perform the crosslinking reaction.
- the basic compound is a conventional basic compound which has a pH of 12 or more as a pH adjusting agent.
- the basic compound is water soluble and has a pH of 12 or higher after mixing with water.
- ester bonds are mainly formed between the hyaluronic acid and the epoxy crosslinking agent
- the pH of the solution is 12 or more
- the ether between the hyaluronic acid and the epoxy crosslinking agent is used. (ether) bonds are mainly produced.
- the basic compound may be a compound containing an alkali metal including sodium, potassium, calcium, and lithium.
- an alkali metal including sodium, potassium, calcium, and lithium.
- sodium hydroxide is preferred but is not limited thereto.
- the solvent is preferably water.
- the mixed solution is vacuum dried at 1 to 30 °C to remove the solvent.
- This step is a low temperature vacuum drying of the mixed solution
- low temperature drying in the present invention is a vacuum drying in which the pressure is adjusted in consideration of the boiling point of water, it is preferable to maintain the temperature of the dried product to 1 to 30 °C, at 1 It is a process of maintaining the pressure which becomes the boiling point of water at 30 degreeC, ie, the pressure within 1-30 mmHg, and continuously removing water evaporating from the crosslinking reaction mixture through drying.
- the concentration of the water-soluble polysaccharide is concentrated to 50 to 99% by weight, preferably 50 to 90% by weight, by removing the solvent.
- the composition is frozen during vacuum drying and the composition obtained after the drying process is completed is a porous sponge (sponge) to achieve the improvement of biodegradation resistance to be pursued in the present invention, if it is above 30 °C under strong base conditions It is difficult to ensure the improvement of the biodegradation resistance to be pursued in the present invention by the rapid decrease in the expressed molecular weight.
- the water-insoluble gel is made of a three-dimensional network structure by crosslinking a water-soluble polysaccharide having a linear structure, a branched branch structure, or a radial structure, and has no solubility in water, but swells only in water. It will be.
- the main variables that influence the physical properties of these water-insoluble gels are the molecular structure, molecular weight, crosslinking density, and type of crosslinking of the polymer used in the crosslinking reaction.
- the molecular weight of the polysaccharides generated during the crosslinking process is minimized, the crosslinking reaction efficiency between the polysaccharides and the epoxy crosslinking agent is maximized, and the water insoluble gels obtained through the crosslinking reaction are mixed with the buffer solution and autoclaved. It is characterized by being able to stably maintain a water-insoluble gel state even under conditions.
- the present invention also provides a water insoluble gel composition
- a water insoluble gel composition comprising a water soluble polysaccharide, an epoxy crosslinker, a basic compound and a solvent.
- the composition preferably comprises 1 to 20% by weight of the water-insoluble gel relative to the total weight of the composition. If the water-insoluble gel is less than 1% by weight, the flowability is too large to be injected into the tissue and then fixed in the tissue, thereby decreasing practicality. If the water-insoluble gel is more than 20% by weight, the flowability is too poor to be injected using a needle or the like. .
- the water-insoluble gel composition according to the present invention may be transparent when the swelling degree of the water-insoluble gel is 30 to 200, translucent milky white when the swelling degree is 10 to 30, and opaque white when the swelling degree is 2 to 10.
- Compositions comprising hyaluronic acid water insoluble gels, which are conventionally sold and sold, are usually completely transparent.
- the composition comprising the water insoluble gel obtained through the present invention is different in appearance depending on the swelling degree of the hyaluronic acid water insoluble gel in the composition. This is because the lower the swelling degree, the different the scattering degree of light, the lower the transparency.
- the water-insoluble gel composition according to the present invention When the water-insoluble gel composition according to the present invention is swelled and autoclaved in a phosphate buffer solution having a pH of 6.5 to 7.5, 70 to 99% by weight relative to the weight of the initially added composition may remain as a water-insoluble gel.
- the ginseng buffer solution is preferably a phosphoric acid concentration of 0.001M or more.
- autoclaving is not limited as long as it is known autoclaving, and may be, for example, performing autoclaving for 20 minutes at about 121 ° C.
- the swelling weight of the composition may be 2 to 200 times the dry weight of the water-insoluble gel remaining after autoclaving. That is, the swelling weight obtained by swelling the water-insoluble gel remaining after autoclaving in an isotonic solution is 2 to 200 times the dry weight of the water-insoluble gel remaining after autoclaving. If the swelling weight is less than 2 times, the strength of the water-insoluble gel is too strong to make it into fine particles, and if it is more than 200 times, the object of the present invention which improves biodegradation resistance cannot be achieved.
- any of the crosslinking functional groups present in the crosslinking agent are in an unreacted state, i.e., an incomplete crosslinking state
- the use of a water insoluble gel as a raw material of the composition to be implanted into biological tissues adversely affects the safety of the implanted composition. Therefore, in the present invention, in the crosslinked water insoluble gel obtained after the crosslinking reaction, in order to minimize the incompletely crosslinked crosslinking agent, the water-insoluble gel which has undergone the crosslinking process is washed and then dried again to swell and redry after the water-insoluble gel obtained after washing. By comparing the swelling degree of the obtained water insoluble gel, the crosslinking conditions in which the incompletely crosslinked crosslinking agent is minimized were optimized.
- a water-insoluble gel composition in which high molecular weight water-soluble polysaccharides are uniformly mixed using a small amount of a crosslinking agent can be obtained. It contains high content of polysaccharides and is excellent in flowability so that it can be injected through the needle, and is stable to autoclave sterilization which must be passed when it is to be used as an insert in the human body, maintaining a low degree of swelling, and having excellent economy and quality.
- the water-insoluble gel composition of the present invention can be used as food, cosmetics, medicines, medical devices, stabilizers, moisturizers, dispersion aids, viscosity regulators, drug delivery carriers, tissue repair fillers, post-adhesion anti-fog film formation, etc. Can be.
- composition for injection drug carrier the composition for mucosal and transdermal absorption drug carrier, the composition for oral drug carrier, the composition for restoring biological tissue after surgery, the composition for preventing tissue adhesion after surgery, the filling composition for molding, the composition for joint insertion, Composition for patch wound treatment dressing, composition for osteoarthritis treatment, composition for adjuvant eye surgery, composition for treating dry eye syndrome, composition for injection for wrinkle treatment, composition for treating gums, composition for treating perforation of tympanic membrane, health food composition or cosmetic composition Can be used.
- HA-Na sodium hyaluronate having a molecular weight of 1.4 million was added to a 50 ml tube with a stopper, and PBS 7.0 was added so that the concentration of HA-Na was 0.5%. Stir until solution.
- HA-Na having a molecular weight of 1.4 million was placed in a 50 ml tube with a stoppered solution of sodium hydroxide (pH 13), followed by stirring until a clear solution was obtained. After the stirring was completed, the mixture was stored for 4 hours in a 40 ° C. water bath, and diluted 20-fold in PBS 7.0 so that the HA-Na concentration became 0.5%.
- HA-Na having a molecular weight of 1.4 million was placed in a 50 ml tube with a stoppered solution of sodium hydroxide (pH 13), followed by stirring until a clear solution was obtained. After the stirring was completed, the prepared HA-Na solution was put on a polyethylene plate and pressed to a thickness of 2 mm, placed in a heating oven set at 40 ° C., dried for 24 hours, and diluted in PBS 7.0 so that the HA-Na concentration was 0.5%. It was.
- HA-Na having a molecular weight of 1.4 million was placed in a 50 ml tube with a stoppered solution of sodium hydroxide (pH 13), followed by stirring until a clear solution was obtained. After the stirring was completed, the prepared HA-Na solution was put on a polyethylene plate and pressed to a thickness of 2 mm, dried at room temperature for 4 days, and diluted in PBS 7.0 to have a HA-Na concentration of 0.5%.
- HA-Na having a molecular weight of 1.4 million was placed in a 50 ml tube with a stoppered solution of sodium hydroxide (pH 13), followed by stirring until a clear solution was obtained. After the stirring was completed, the prepared HA-Na solution was put on a polyethylene plate and pressed to a thickness of 2 mm, placed in a vacuum oven set at 40 ° C., and adjusted to a pressure of 10 mm Hg or less and dried for 24 hours, followed by PBS 7.0. It was diluted to make HA-Na concentration 0.5%.
- HA-Na having a molecular weight of 1.4 million was placed in a 50 ml tube with a stoppered solution of sodium hydroxide (pH 13), followed by stirring until a clear solution was obtained. After the stirring was completed, the prepared HA-Na solution was put on a polyethylene plate and pressed to a thickness of 2 mm, placed in a vacuum oven set at 30 ° C., and adjusted to a pressure of 10 mm Hg or less and dried for 24 hours, followed by PBS 7.0. It was diluted to make HA-Na concentration 0.5%.
- the experiment which measures the viscosity of the composition by Comparative Examples 1-5 and Example 1 was performed.
- the viscosity of the solution was measured using a Brook filed disc viscometer so that the concentration of sodium hyaluronate (molecular weight of 1.4 million) was 0.5% in 0.02M phosphate buffer solution (pH 7.0, 0.8 wt% NaCl, hereinafter PBS 7.0).
- the viscosity measurement temperature was 25 degreeC
- the disk specification was # 62
- the disk rotation speed was 30 rpm.
- Table 1 The results are shown in Table 1 below. As can be seen in Table 1, it was confirmed that the molecular weight of hyaluronic acid is sharply reduced under the conditions of applying a strong base through Comparative Example 1 and Comparative Examples 2 to 5, Example 1. And it was confirmed that the molecular weight decrease of hyaluronic acid generated in the strong base aqueous solution state can be suppressed through a low temperature vacuum process below 30 °C.
- aqueous sodium hydroxide solution pH 13
- HA-Na having a molecular weight of 1.4 million
- BDDE aqueous sodium hydroxide solution
- the rate at which the crosslinking agent introduced according to the crosslinking process of the compositions according to Comparative Examples 2 and 2 participates in the crosslinking reaction was evaluated. Agitation of each composition was completed and the supernatant was taken to measure unreacted BDDE. After crosslinking reaction, the mixture for crosslinking was washed in PBS 7.0, and then butanediol diglycidyl ether (BDDE) contained in PBS 7.0 was used for gas chromatography. , Through GC). As an internal standard, neopentyl diglycidyl ether (NPDGE) was used. Detailed measurement conditions are as follows.
- Oven temp. 80 ° C., 2 minutes ⁇ 10 ° C./minute, temperature increase ⁇ 200 ° C., 0 minutes ⁇ 25 ° C./minute, temperature increase ⁇ 250 ° C., 0 minutes
- HA-Na with a molecular weight of 1.4 million each was added.
- the pH was adjusted to 12 using distilled water, a hydrogen chloride solution adjusted to pH 1 using hydrogen chloride, and sodium hydroxide.
- 9 g of each adjusted sodium hydroxide aqueous solution was added, and 50 mg of butanediol diglycidyl ether (1,4-butandiol diglycidyl ether, hereinafter BDDE) was added as a crosslinking agent. After adding BDDE, it was stirred until it became a clear solution, thereby preparing a mixture for crosslinking. After stirring was completed, vacuum drying in the same manner as in Example 1 was carried out for 24 hours.
- HA-Na 1 g of HA-Na with a molecular weight of 1.4 million was put into three 50 ml tubes with stoppers, and 9 g of aqueous sodium hydroxide solution with pH adjusted to 12.5, 13 and 14 using sodium hydroxide. 50 mg each of BDDE was added as a crosslinking agent. After the addition of BDDE, the mixture was stirred until a clear solution was completed to complete the crosslinking mixture. After stirring was completed, the pH of the crosslinking mixture was measured and vacuum drying of the same method as in Example 1 was performed for 24 hours.
- Sterilization Stability (Dry weight of water-insoluble gel after autoclaving / Dry weight of water-insoluble gel before autoclaving) ⁇ 100
- the epoxy-based crosslinking agent crosslinks the ester when the pH is acidic and the ether bonds when the pH is basic, depending on the pH of the solution in which the polysaccharide is dissolved.
- the pH of the crosslinking mixture prepared by mixing the polysaccharide with the epoxy crosslinking agent, distilled water, and the pH adjusting agent is 12 or more, so as to maintain the ether bond. It was confirmed that it should be produced sufficiently.
- Comparative Examples 10 and 11 and Examples 6 to 9 were compared to confirm the lower limit and the upper limit of the amount of crosslinking agent.
- the crosslinking agent input and gel yield were calculated by the following equations (2) and (3), respectively. The results are shown in Table 5 below.
- the epoxy-based crosslinking agent was added in an amount of 0.05 to 40 mol% based on the crosslinking density to be suitable for the low temperature vacuum drying process.
- Increasing the amount of crosslinking agent decreased the gel yield and decreased the mechanical strength of the water-insoluble gel showed that the epoxy-based crosslinking agent can crosslink, but at the same time have the effect of cutting the molecular chain of polysaccharides.
- Crosslinking agent input (mol%) [(Epoxy functional group crosslinking agent x crosslinking agent input (g) / crosslinking agent molecular weight (g / mol)) / (number of hydroxy functional groups bondable in water-soluble polymer repeat unit ⁇ polysaccharide input (g) / polysaccharide Repeating unit molecular weight (g / mol))] ⁇ 100
- One side was used for measurement of moisture content, the other side was placed in 50 g of PBS 7.0 and stored for 24 hours. A sample placed in PBS 7.0 was visually observed to confirm that a water-insoluble gel was formed, and autoclaved at 121 ° C. for 15 minutes while placed in PBS 7.0. In order to confirm the stability of the water insoluble gel, the autoclaved water insoluble gel was further washed with distilled water and dried to measure the weight.
- the sample placed in PBS 7.0 was visually observed to see if a water-insoluble gel was produced.
- the sample was autoclaved at 121 ° C. for 15 minutes while being placed in PBS 7.0.
- the autoclaved water insoluble gel was further washed with distilled water and dried to measure the weight.
- the crosslinking efficiency according to the crosslinking time was evaluated to determine a suitable crosslinking time.
- the samples prepared for each low temperature vacuum drying time was put in a thermal residual meter to measure the moisture content. The measurement was carried out under the condition that the weight change was measured at an interval of 5 minutes at 105 ° C. for 3 hours. The measurement results are shown in Table 6 below.
- the water content contained in the crosslinking mixture is more important factor than the crosslinking time in the low temperature vacuum drying process, and it is appropriate to maintain at least 1 hour after the water content is 20% or less in the crosslinking mixture. Confirmed.
- Example 22 6 g of 50 ml tubes with stoppers were added 4 g of sodium hydroxide aqueous solution adjusted to pH 13 using sodium hydroxide, and 40 mg, 200 mg, 400 mg and 600 mg of HA-Na having a molecular weight of 1.4 million, respectively. , 800 mg, 1.6 g, and 4 g were added and then stirred. After stirring was completed, vacuum drying in the same manner as in Example 1 was carried out, and after vacuum drying, PBS 7.0 was added so that the concentration of HA-Na was 0.5% by weight, and when HA-Na was completely dissolved, a viscosity measurement was performed. It carried out using a viscometer. After drying, Example 22 was added to PBS 7.0, stirred for 24 hours, autoclaved at 121 ° C. for 15 minutes, washed again with distilled water, and dried again.
- the water-soluble polysaccharide input amount of the composition according to Comparative Examples 17 and 18 and Examples 16 to 22 was measured.
- the concentration of the polysaccharide is kept high from the beginning, the water content in the crosslinking mixture can be reduced, thereby increasing the crosslinking reaction rate.
- HA-Na having a molecular weight of 7,100 Da, 83,000 Da, 420,000 Da, and 1.4 million Da based on the number average molecular weight was put in a 50 ml tube with a stopper as shown in Table 8 below, using 1 g of sodium hydroxide.
- 9 g of aqueous sodium hydroxide solution having a pH adjusted to 13 and 10 mg (2 mol%) of BDDE were mixed and stirred. After the stirring was completed, when the mixture for crosslinking was completely transparent, vacuum drying in the same manner as in Example 1 was performed for 24 hours, and after vacuum drying, the mixture was stirred in PBS 7.0 for 24 hours. After washing with PBS 7.0 for 24 hours, it was visually checked for the presence of a water insoluble gel, autoclaved at 121 ° C. for 15 minutes, washed again with distilled water, and re-dried.
- hyaluronic acid In the case of hyaluronic acid, a molecular weight of about 1 million Da is generally applied to the crosslinking reaction. In order to cope with a decrease in molecular weight occurring during the crosslinking process, hyaluronic acid having a molecular weight of several million Da or more is also applied to the crosslinking reaction. However, such a method increases the cost and ensures mixed heterogeneity due to high viscosity when preparing a mixture for crosslinking.
- a product containing a hyaluronic acid crosslinked product which is an existing product, is a product of Perlane [existing product 1 (P)] of Q-med, Juvederm-Ultra [existing product 2 (JU)] of Allergane, and Esthelis Basic [of Antheis company].
- Existing product 3 (EB)] and Glytone-2 [existing product 4 (G-2)] of PFDC were used, and each product was purchased through a hospital for research.
- the re-dried water insoluble gel was ground to a powder of 100 ⁇ m or less.
- the water-insoluble gel prepared in powder and PBS 7.0 were mixed so that the content of the water-insoluble gel was 5 w / v%.
- Scanning performance was measured with the tensile force meter set to the compressive strength measurement mode. After removing the cap of the syringe containing the composition containing the hyaluronic acid gel and mounting a needle having a size of 27 1 / 2G, the syringe was fixed vertically on the tensile forceometer measuring plate with the needle downward. . The tension force meter was operated to push the plunge mounted on the syringe at a rate of 1 mm / sec, and the force following compression was measured until the contents contained in the pores were completely emptied.
- the autoclaved hyaluronic acid composition was mixed with 5 mg of hyaluronic acid and 0.5 ml of a solution of hyaluronidase dissolved at 200 IU / ml to mix 20 IU of hyaluronidase per 1 mg of hyaluronic acid.
- Hyaluronic acid and hyaluronidase were mixed and then stored at 37 ° C. for 8 hours. After 8 hours, 4 ml of 0.1N HCl solution was added to stir vigorously, and distilled water was added to make a total of 10 ml. After stirring for one day to dissolve the uncrosslinked hyaluronic acid, the supernatant was taken by centrifugation for 20 minutes at 3000rpm.
- Hyaluronic acid contained in the supernatant was quantified to determine the degree of degradation by enzymatic degradation by the following equation (4).
- Enzymatic Resistance ⁇ (Hydraulic Crosslinked Hyaluronic Acid Gel Content (mg)-Hyaluronic Acid Concentration Measured after Enzyme Injection (mg / ml) ⁇ 10 (ml)) / Crosslinked Before Enzyme Input Hyaluronic Acid Gel Content (mg) ⁇ ⁇ 100
- Table 9 The results are shown in Table 9 below. As can be seen in Table 9, the composition presented in the present invention is 2.5% higher than the hyaluronic acid content of 5%, while the hyaluronic acid content of the existing product is 2%, but it can be seen that the injection performance is equal or better. In addition, in the enzymatic digestion experiments, the resistance to enzymatic degradation was excellent, and after transplantation into the biological tissues, the retention time in the biological tissues was confirmed to be longer.
- Example 11 The transparency of the compositions of Example 11 and Examples 23 to 29 was observed.
- the water-insoluble gels were pulverized to a dry state to 100 ⁇ m or less, mixed with PBS 7.0 to a fully swelled state, centrifuged to remove the supernatant, and the remaining water-insoluble gel was added to a 1 ml glass syringe. After filling and autoclaving, the appearance was visually observed. The results are shown in Table 10 below.
Abstract
Description
구분 | 가교공정 | 점도측정 시 히알루론산 농도(중량%) | 점도(cp) |
비교예 1 | 가교공정 거치지 않음 | 0.5 중량% | 152 |
비교예 2 | 용액상 가교/40℃/4시간 | 0.5 중량% | 12.5 |
비교예 3 | 가열건조/40℃/24 시간 | 0.5 중량% | 10.8 |
비교예 4 | 실온건조/4일 | 0.5 중량% | 10.7 |
비교예 5 | 진공건조/40℃/24시간 | 0.5 중량% | 22.4 |
실시예 1 | 진공건조/30℃/24시간 | 0.5 중량% | 47.5 |
Ions (m/z) | 57 | 71 | 85 | 100 | 127 |
Dwell time (msec) | 50 | 50 | 50 | 50 | 50 |
구분 | 가교공정 | GC측정용 시료 내 이론적 BDDE 함류량(mg) | 미반응 가교제량(mg) | 가교반응 참여율(%) |
비교예 6 | 용액상 가교 | 20 | 15.4 | 23 |
실시예 2 | 진공건조/30℃/24시간 | 200 | 9.5 | 52.5 |
구분 | 가교용 혼합물의 pH | 멸균안정성 (%) |
비교예 7 | 1.04 | 0 |
비교예 8 | 6.4 | 0 |
비교예 9 | 11.6 | 0 |
실시예 3 | 12.1 | 91 |
실시예 4 | 12.8 | 95 |
실시예 5 | 13.5 | 96 |
구분 | 가교제 투입량(몰%) | 겔 수율(%) | 멸균안정성 (%) | 가압멸균 후 팽윤도 |
비교예 10 | 0.02 | 0 | 0 | 0 |
비교예 11 | 60 | 0 | 0 | 0 |
실시예 6 | 0.05 | 5 | 0 | 0 |
실시예 7 | 0.1 | 24 | 50 | 측정불가(*) |
실시예 8 | 10 | 98 | 94 | 6.2 |
실시예 9 | 40 | 25 | 측정불가 | 측정불가 |
구분 | 건조시간 | 수분함량(%) | 겔수율(%) | 멸균안정성(%) | 가압멸균 후 팽윤도 |
비교예 12 | 1 | 87 | 0 | 0 | - |
비교예 13 | 2 | 61 | 0 | 0 | - |
비교예 14 | 3 | 42 | 0 | 0 | - |
비교예 15 | 4 | 24 | 0 | 0 | - |
실시예 10 | 5 | 15 | 65 | 74 | 25 |
실시예 11 | 6 | 12 | 88 | 85 | 15 |
실시예 12 | 7 | 8 | 94 | 94 | 9.5 |
실시예 13 | 8 | 8 | 95 | 95 | 8.9 |
실시예 14 | 9 | 7 | 96 | 95 | 9.2 |
실시예 15 | 10 | 6 | 97 | 96 | 9.0 |
구분 | 가교용 혼합물 내HA농도(중량부*) | 가교제 투입량(몰%) | 저온진공건조공정을 거친 후 점도(0.5 중량%, cp) | 겔 수율(%) |
비교예 17 | 0.5 | 0 | 12.5 | 측정불가 |
실시예 16 | 1 | 0 | 18 | |
실시예 17 | 5 | 0 | 25 | |
실시예 18 | 10 | 0 | 47.5 | |
실시예 19 | 15 | 0 | 55 | |
실시예 20 | 20 | 0 | 66 | |
실시예 21 | 40 | 0 | 72 | |
실시예 22 | 100 | 0 | 77 | |
비교예 18 | 150 | 2 | 측정불가 | 34 |
구분 | 수평균 분자량으로 구분된 HA-Na 투입량 (g) | 겔 수율(%) | 멸균안정성 (%) | 멸균 후 팽윤도 | |||
7,100 Da | 83,000 Da | 42만 Da | 140만 Da | ||||
비교예 19 | 1.0 | 0 | 0 | 0 | 0 | 0 | 측정불가 |
비교예 20 | 0 | 1.0 | 0 | 0 | 0 | 0 | 측정불가 |
비교예 21 | 0 | 0 | 1.0 | 0 | 85 | 0 | 측정불가 |
비교예 22 | 0.5 | 0 | 0 | 0.5 | 81.6 | 0 | 측정불가 |
비교예 23 | 0 | 0.5 | 0 | 0.5 | 85.3 | 0 | 측정불가 |
실시예 23 | 0 | 0 | 0.5 | 0.5 | 96 | 75 | 180배 이상 |
제품 | 주사성능 (N) | 효소분해 저항성(%) |
실시예 11 | 25 ± 2 | 68 |
기존제품 1 (P) | 24 ± 1 | 39.5 |
기존제품 2 (J-U) | 31 ± 2 | 23.2 |
기존제품 3 (E-B) | 33 ± 5 | 0 |
기존제품 4 (G-2) | 31 ± 7 | 0 |
구분 | HA-Na 분자량(수평균/Da) | 가교제 투입량(몰 %) | 멸균 후 팽윤도 | 외관 |
실시예 11 | 140만 | 2 | 180배 이상 | 투명 |
실시예 23 | 90만 | 2 | 15 | 반투명 |
실시예 24 | 140만 | 0.1 | 75배 이상 | 투명 |
실시예 25 | 140만 | 0.5 | 28 | 반투명 |
실시예 26 | 140만 | 4 | 8.8 | 불투명 |
실시예 27 | 140만 | 8 | 7.1 | 불투명 |
실시예 28 | 140만 | 16 | 5.4 | 불투명 |
실시예 29 | 140만 | 20 | 3.5 | 불투명 |
Claims (14)
- 수용성 다당류, 에폭시 가교제, 염기성 화합물 및 용매를 혼합하는 단계; 및상기 혼합액을 1 내지 30℃에서 진공건조하여 용매를 제거하는 단계;를 포함하는 수불용성 겔 조성물의 제조방법.
- 제 1항에 있어서,상기 진공건조는 1 내지 30mmHg 하에서 이루어지는 것인 수불용성 겔 조성물의 제조방법.
- 제 1항에 있어서,상기 용매 제거하는 단계는 수용성 다당류의 농도를 50 내지 99중량%로 농축하는 것인 수불용성 겔 조성물의 제조방법.
- 제 1항에 있어서,상기 수용성 다당류는 분자량이 50만 내지 500만 달톤인 수불용성 겔 조성물의 제조방법.
- 제 1항에 있어서,상기 수용성 다당류는 용매 중량 100부에 대하여 1 내지 100중량부인 수불용성 겔 조성물의 제조방법.
- 제 1항에 있어서,상기 수용성 다당류는 히아루론산(hyaluronic acid), 히아루론산염, 폴리감마글루탐산(poly-γ-glutamic acid), 폴리감마글루탐산염, 한천(agar), 알진산(alginic acid), 알진산염(alginate), 카라기난(carrageenan), 퍼셀라란(furcellaran), 펙틴(pectin), 아라비아 고무(arabic gum), 카라야 고무(karaya gum), 트라가칸스 고무(tragacanth gum), 가티 고무(ghatti gum), 구아 고무(guar gum), 메뚜기콩 고무(locust bean gum), 사이리엄 고무(psyllium seed gum), 젤라틴(gleatin), 키틴(chitin), 덱스트란(dextran), 잔탄 고무(xanthane gum), 키토산(chitosan), 콘드로이친-4-설페이트(chondroitin-4-sulfate), 콘드로이친-6-설페이트(chondroitin-6-sulfate) 및 녹말(starch)로 이루어진 군에서 선택되는 1종 이상인 수불용성 겔 조성물의 제조방법.
- 제 1항에 있어서,상기 에폭시 가교제는 수용성 다당류 내의 히드록시기 1몰에 대하여 0.01 내지 60몰부인 수불용성 겔 조성물의 제조방법.
- 제 1항에 있어서,상기 에폭시 가교제는 에피클로로히드린(epichlorohydrin), 에피브로모히드린(epibromohydrin), 부탄디올디글리시딜에테르(1,4-butandiol diglycidyl ether), 에틸렌글리콜디글리시딜에테르(ethylene glycol diglycidyl ether), 헥산디올디글리시딜에테르(1,6-hexanediol diglycidyl ether), 프로필렌글리콜디글리시딜에테르(propylene glycol diglycidyl ether), 폴리에틸렌글리콘디글리시딜에테르(polyethylene glycol diglycidyl ether), 폴리프로필렌글리콜디글리시딜에테르(polypropylene glycol diglycidyl ether), 폴리테트라메틸렌글리콜디글리시딜에테르(polytetramethylene glycol diglycidyl ether), 네오펜틸글리콜디글리시딜에테르(neopentyl glycol diglycidyl ether), 폴리글리세롤폴리글리시딜에테르(polyglycerol polyglycidyl ether), 디글리세롤폴리그리시딜에테르(diglycerol polyglycidyl ether), 글리세롤폴리글리시딜에테르(glycerol polyglycidyl ether), 트리메틸프로판폴리글리시딜에테르(trimethlypropane polyglycidyl ether), 비스에폭시프로폭시에틸렌(1,2-(bis(2,3-epoxypropoxy)ethylene), 펜타에리쓰리톨폴리글리시딜에테르(pentaerythritol polyglycidyl ether) 및 소르비톨폴리글리시딜에테르(sorbitol polyglycidyl ether)로 이루어진 군에서 선택되는 1종 이상인 수불용성 겔 조성물의 제조방법.
- 제 1항에 있어서,상기 염기성 화합물은 나트륨, 칼륨, 칼슘, 리튬을 포함하는 알칼리 금속을 포함하는 화합물인 수불용성 겔 조성물의 제조방법.
- 제 1 항 내지 제 9항 중 어느 하나의 제조방법에 의해 제조된 수불용성 겔 조성물.
- 제 10항에 있어서,상기 조성물은 수불용성 겔을 조성물 총 중량에 대하여 1 내지 20중량% 포함하는 것인 수불용성 겔 조성물.
- 제 10항에 있어서,상기 조성물은 수불용성 겔의 팽윤도가 30 내지 200이면 투명, 팽윤도가 10 내지 30이면 반투명 유백색 및 팽윤도가 2 내지 10이면 불투명 백색인 수불용성 겔 조성물.
- 제 10항에 있어서,상기 조성물을 pH 6.5 내지 7.5인 인산염 완충용액에 넣고 팽윤 및 가압멸균하였을 때, 최초 투입된 조성물 중량에 대하여 70 내지 99중량%가 수불용성 겔로서 잔존하는 것인 수불용성 겔 조성물.
- 제 13항에 있어서,상기 조성물의 팽윤중량은 가압멸균 후 잔존하는 수불용성 겔의 건조중량의 2 내지 200배인 것인 수불용성 겔 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12851320.7A EP2783702B1 (en) | 2011-11-24 | 2012-11-21 | Water insoluble gel composition and method for preparing same |
US14/359,520 US9493636B2 (en) | 2011-11-24 | 2012-11-21 | Water insoluble gel composition and method for preparing same |
CN201280057847.2A CN103974722B (zh) | 2011-11-24 | 2012-11-21 | 水不溶性凝胶组合物及其制备方法 |
JP2014543417A JP6106686B2 (ja) | 2011-11-24 | 2012-11-21 | 水不溶性ゲル組成物およびその製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0123485 | 2011-11-24 | ||
KR1020110123485A KR101428145B1 (ko) | 2011-11-24 | 2011-11-24 | 수불용성 겔 조성물 및 그 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013077620A1 true WO2013077620A1 (ko) | 2013-05-30 |
Family
ID=48470010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/009853 WO2013077620A1 (ko) | 2011-11-24 | 2012-11-21 | 수불용성 겔 조성물 및 그 제조방법 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9493636B2 (ko) |
EP (1) | EP2783702B1 (ko) |
JP (1) | JP6106686B2 (ko) |
KR (1) | KR101428145B1 (ko) |
CN (1) | CN103974722B (ko) |
WO (1) | WO2013077620A1 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103937013A (zh) * | 2014-01-13 | 2014-07-23 | 北京化工大学 | 一种琼脂凝胶微球及其制备方法 |
EP3081232A4 (en) * | 2013-12-09 | 2017-06-14 | New Medic Co., Ltd. | Hyaluronic acid gel composition having sustained release property |
CN114588309A (zh) * | 2022-03-09 | 2022-06-07 | 湖南玉津医疗科技有限公司 | 一种双交联的多重微孔止血海绵的制备方法 |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US8962023B2 (en) | 2004-09-28 | 2015-02-24 | Atrium Medical Corporation | UV cured gel and method of making |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
WO2012009707A2 (en) | 2010-07-16 | 2012-01-19 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
KR101886413B1 (ko) * | 2016-03-16 | 2018-08-10 | 주식회사 엘앤씨바이오 | 히알루론산에 기반한 연조직 충진 조성물의 제조 방법 |
CN106563155A (zh) * | 2016-10-18 | 2017-04-19 | 宁波大学 | 一种用于修复皮肤的凝胶的制备方法 |
CN107880282B (zh) * | 2016-12-29 | 2020-09-29 | 北京键凯科技股份有限公司 | 一种注射用多元甘醇环氧衍生物交联的透明质酸钠凝胶及其制备方法 |
CN107417801B (zh) * | 2017-06-20 | 2020-11-24 | 中国人民解放军东部战区总医院 | 一种可注射水凝胶及其制备方法与应用 |
WO2019001472A1 (zh) * | 2017-06-28 | 2019-01-03 | 北京键凯科技股份有限公司 | 分枝型多元甘醇环氧衍生物交联透明质酸钠凝胶及其制备和应用 |
KR102017741B1 (ko) * | 2017-12-01 | 2019-09-03 | 주식회사 리엔젠 | 비타민 c 유도체를 고정화한 폴리감마 글루탐산계 진피 충전제 조성물 및 그 제조방법 |
KR102053913B1 (ko) * | 2018-10-12 | 2019-12-09 | 바이오플러스 주식회사 | 다당류를 이용한 가교 중점도 용액의 제조 방법 |
KR102610937B1 (ko) | 2018-10-30 | 2023-12-08 | (주)아모레퍼시픽 | 가교 히알루론산 조성물 및 이의 제조방법 |
CN109267906A (zh) * | 2018-11-21 | 2019-01-25 | 苏州大学 | 一种可切换透光状态的智能窗户 |
SE544700C2 (en) * | 2019-05-15 | 2022-10-18 | Stora Enso Oyj | Use of bonding resin |
KR102425496B1 (ko) * | 2020-05-08 | 2022-07-26 | 주식회사 종근당 | 고탄성, 고점도 및 고유효 가교율을 갖는 히알루론산 가교체, 및 이의 제조방법 |
KR102483189B1 (ko) * | 2020-11-17 | 2022-12-30 | 동국제약 주식회사 | 가교 폴리감마글루탐산 하이드로겔의 제조방법 |
CN113061265A (zh) * | 2021-02-18 | 2021-07-02 | 中国人民解放军空军军医大学 | 一种多糖类水凝胶,其制备方法及其应用 |
CN114369322A (zh) * | 2022-01-18 | 2022-04-19 | 山东新昊顺为新材料科技有限公司 | 一种高分子吸水树脂的制备方法 |
CN114702701B (zh) * | 2022-04-06 | 2023-10-27 | 厦门爱逸零食研究所有限公司 | 一种黄原胶琼胶复合衍生物、及其制备方法与应用 |
CN115433353A (zh) * | 2022-09-27 | 2022-12-06 | 杨巧云 | 多聚二醇二缩水甘油醚的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000012760A (ko) * | 1999-12-23 | 2000-03-06 | 성재갑 | 하이드로 겔 조성물 |
KR20060028604A (ko) * | 2004-09-25 | 2006-03-30 | 경북대학교 산학협력단 | 수용성 고분자 나노 하이드로겔의 제조방법 |
KR20070004159A (ko) * | 2005-07-04 | 2007-01-09 | 주식회사 엘지생명과학 | 히알루론산 가교물의 제조방법 |
KR20110060257A (ko) * | 2009-11-30 | 2011-06-08 | (주)아모레퍼시픽 | 하이드로겔 가교체를 형성하여 효소를 안정화시키는 방법 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6174999B1 (en) * | 1987-09-18 | 2001-01-16 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
US4937270A (en) * | 1987-09-18 | 1990-06-26 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
US6294202B1 (en) * | 1994-10-06 | 2001-09-25 | Genzyme Corporation | Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers |
TW574301B (en) * | 2001-05-02 | 2004-02-01 | Ind Tech Res Inst | Manufacturing method of epoxide crosslinked polysaccharides matrix |
TWI251596B (en) * | 2002-12-31 | 2006-03-21 | Ind Tech Res Inst | Method for producing a double-crosslinked hyaluronate material |
AU2003901834A0 (en) * | 2003-04-17 | 2003-05-01 | Clearcoll Pty Ltd | Cross-linked polysaccharide compositions |
WO2007129828A1 (en) * | 2006-05-04 | 2007-11-15 | Seoul National University Industry Foundation | Preparation method of porous hyaluronic acid sponge for cell delivery system |
IT1395392B1 (it) | 2009-08-27 | 2012-09-14 | Fidia Farmaceutici | Geli viscoelastici come nuovi filler |
KR101327083B1 (ko) * | 2010-05-07 | 2013-11-07 | (주)아모레퍼시픽 | 수불용성 겔 조성물 제조 방법 및 그에 의해 제조된 수불용성 겔 |
KR101316401B1 (ko) * | 2010-05-07 | 2013-10-10 | (주)아모레퍼시픽 | 수불용성 겔 조성물의 고체상 제조 방법 및 그에 의해 제조된 수불용성 겔 |
-
2011
- 2011-11-24 KR KR1020110123485A patent/KR101428145B1/ko active IP Right Grant
-
2012
- 2012-11-21 JP JP2014543417A patent/JP6106686B2/ja active Active
- 2012-11-21 WO PCT/KR2012/009853 patent/WO2013077620A1/ko active Application Filing
- 2012-11-21 CN CN201280057847.2A patent/CN103974722B/zh active Active
- 2012-11-21 US US14/359,520 patent/US9493636B2/en active Active
- 2012-11-21 EP EP12851320.7A patent/EP2783702B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000012760A (ko) * | 1999-12-23 | 2000-03-06 | 성재갑 | 하이드로 겔 조성물 |
KR20060028604A (ko) * | 2004-09-25 | 2006-03-30 | 경북대학교 산학협력단 | 수용성 고분자 나노 하이드로겔의 제조방법 |
KR20070004159A (ko) * | 2005-07-04 | 2007-01-09 | 주식회사 엘지생명과학 | 히알루론산 가교물의 제조방법 |
KR20110060257A (ko) * | 2009-11-30 | 2011-06-08 | (주)아모레퍼시픽 | 하이드로겔 가교체를 형성하여 효소를 안정화시키는 방법 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3081232A4 (en) * | 2013-12-09 | 2017-06-14 | New Medic Co., Ltd. | Hyaluronic acid gel composition having sustained release property |
CN103937013A (zh) * | 2014-01-13 | 2014-07-23 | 北京化工大学 | 一种琼脂凝胶微球及其制备方法 |
CN114588309A (zh) * | 2022-03-09 | 2022-06-07 | 湖南玉津医疗科技有限公司 | 一种双交联的多重微孔止血海绵的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2783702B1 (en) | 2018-11-14 |
CN103974722A (zh) | 2014-08-06 |
EP2783702A1 (en) | 2014-10-01 |
EP2783702A4 (en) | 2015-08-12 |
US9493636B2 (en) | 2016-11-15 |
KR101428145B1 (ko) | 2014-08-08 |
JP2015500895A (ja) | 2015-01-08 |
KR20130057640A (ko) | 2013-06-03 |
CN103974722B (zh) | 2017-04-26 |
US20140331894A1 (en) | 2014-11-13 |
JP6106686B2 (ja) | 2017-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013077620A1 (ko) | 수불용성 겔 조성물 및 그 제조방법 | |
US11180576B2 (en) | Combination of cross-linked hyaluronic acids and method of preparing the same | |
WO2013180458A1 (ko) | 약물전달용 가교물 하이드로 젤 및 그 하이드로 젤의 제조방법 | |
WO2012008722A2 (ko) | 조직 증강용 충전 조성물 | |
WO2017039030A1 (ko) | 히알루론산 조성물 및 그의 제조방법 | |
WO2016209062A1 (en) | Two-component bioink, 3d biomaterial comprising the same and method for preparing the same | |
WO2018080221A1 (ko) | 생체친화형 하이드로젤 및 제조방법 | |
WO2012099293A1 (ko) | 방사선 가교화된 콜라겐 겔 및 그 제조방법과 사용방법 | |
WO2016159734A1 (ko) | 카테콜 기 및 산화된 카테콜 기가 도입되어 가교된 키토산으로 코팅된 무출혈 주사바늘 | |
WO2016043547A1 (ko) | 조직 수복용 조성물 및 이의 제조방법 | |
WO2018199698A1 (ko) | 섬유화 무세포 진피 기질 및 생체적합성 고분자를 포함하는 조성물 및 이의 제조 방법 | |
KR101869988B1 (ko) | 점탄성 히알루론산 가교물 제조용 조성물, 및 이를 이용하여 얻은 히알루론산 가교물 | |
Ma et al. | Injectable hyaluronic acid/poly (γ-glutamic acid) hydrogel with step-by-step tunable properties for soft tissue engineering | |
Kesenci et al. | Poly (ε-caprolactone-co-D, L-lactide)/silk fibroin composite materials: Preparation and characterization | |
WO2021125373A1 (ko) | 지방조직 유래 세포외기질을 포함하는 의료용 조성물 및 그 제조방법 | |
WO2017018717A1 (ko) | 진피 필러용 하이드로젤 조성물 | |
WO2023282658A1 (ko) | 다중 가교된 온도감응성 하이드로겔 제조용 조성물 및 이의 용도 | |
WO2022050694A1 (ko) | 연골 또는 골 질환의 예방 또는 치료용 생체모사 조직 접착성 하이드로젤 패치 | |
WO2022154645A1 (ko) | 히알루론산, 폴리에틸렌글리콜 및 실리콘 함유 성분을 포함하는 생체적합성 하이드로겔 | |
WO2021246764A1 (ko) | 고분자 마이크로 입자의 제조방법, 고분자 마이크로 입자, 이를 포함하는 의료용 조성물, 미용 조성물, 의료 용품 및 미용 용품 | |
WO2022019461A1 (ko) | 식용 가능한 시트형 물품 | |
WO2023191553A1 (ko) | 신축성 자가치유 하이드로젤 | |
WO2021085775A1 (ko) | 골 무기질 성분을 함유하는 복합 탈회골 조성물 및 그 제조공정 | |
WO2023172037A1 (ko) | 페이스트 조성물, 생분해성 주사용 페이스트 및 이의 제조방법 | |
WO2023244011A1 (ko) | 복합체, 이의 제조방법 및 이를 이용한 성형용 필러 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12851320 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14359520 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2014543417 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012851320 Country of ref document: EP |